• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SCHEDULE 13G filed by Indaptus Therapeutics Inc.

    2/18/25 4:03:06 PM ET
    $INDP
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $INDP alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    Indaptus Therapeutics, Inc.

    (Name of Issuer)


    Common Stock

    (Title of Class of Securities)


    45339J105

    (CUSIP Number)


    02/13/2025

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox not checked   Rule 13d-1(b)
    Checkbox checked   Rule 13d-1(c)
    Checkbox not checked   Rule 13d-1(d)






    SCHEDULE 13G

    CUSIP No.
    45339J105


    1Names of Reporting Persons

    YA II PN, Ltd.
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    CAYMAN ISLANDS
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    1,410,916.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    1,410,916.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    1,410,916.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    9.99 %
    12Type of Reporting Person (See Instructions)

    OO


    SCHEDULE 13G

    CUSIP No.
    45339J105


    1Names of Reporting Persons

    YA Global Investments II (U.S.), LP
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    1,410,916.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    1,410,916.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    1,410,916.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    9.99 %
    12Type of Reporting Person (See Instructions)

    OO


    SCHEDULE 13G

    CUSIP No.
    45339J105


    1Names of Reporting Persons

    Yorkville Advisors Global, LP
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    1,410,916.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    1,410,916.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    1,410,916.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    9.99 %
    12Type of Reporting Person (See Instructions)

    OO


    SCHEDULE 13G

    CUSIP No.
    45339J105


    1Names of Reporting Persons

    Yorkville Advisors Global II, LLC
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    1,410,916.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    1,410,916.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    1,410,916.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    9.99 %
    12Type of Reporting Person (See Instructions)

    OO


    SCHEDULE 13G

    CUSIP No.
    45339J105


    1Names of Reporting Persons

    YAII GP, LP
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    1,410,916.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    1,410,916.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    1,410,916.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    9.99 %
    12Type of Reporting Person (See Instructions)

    OO


    SCHEDULE 13G

    CUSIP No.
    45339J105


    1Names of Reporting Persons

    YAII GP II, LLC
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    1,410,916.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    1,410,916.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    1,410,916.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    9.99 %
    12Type of Reporting Person (See Instructions)

    OO


    SCHEDULE 13G

    CUSIP No.
    45339J105


    1Names of Reporting Persons

    Mark Angelo
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    NEW JERSEY
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    1,410,916.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    1,410,916.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    1,410,916.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    9.99 %
    12Type of Reporting Person (See Instructions)

    OO


    SCHEDULE 13G

    CUSIP No.
    45339J105


    1Names of Reporting Persons

    SC-Sigma Global Partners, LP
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    1,410,916.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    1,410,916.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    1,410,916.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    9.99 %
    12Type of Reporting Person (See Instructions)

    OO


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    Indaptus Therapeutics, Inc.
    (b)Address of issuer's principal executive offices:

    3 Columbus Circle, 15th Floor New York, NY, 10019
    Item 2. 
    (a)Name of person filing:

    YA II PN, Ltd.
    (b)Address or principal business office or, if none, residence:

    1012 Springfield Ave., Mountainside, NJ 07092
    (c)Citizenship:

    Cayman Islands
    (d)Title of class of securities:

    Common Stock
    (e)CUSIP No.:

    45339J105
    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)Checkbox not checked   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)Checkbox not checked   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)Checkbox not checked   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)Checkbox not checked   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)Checkbox not checked   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)Checkbox not checked   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)Checkbox not checked   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)Checkbox not checked   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)Checkbox not checked   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)Checkbox not checked   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
           please specify the type of institution:
    (k)Checkbox checked   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
     
    Item 4.Ownership
    (a)Amount beneficially owned:

    1,410,916
    (b)Percent of class:

    9.99  %
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    0

     (ii) Shared power to vote or to direct the vote:

    1,410,916

     (iii) Sole power to dispose or to direct the disposition of:

    0

     (iv) Shared power to dispose or to direct the disposition of:

    1,410,916

    Item 5.Ownership of 5 Percent or Less of a Class.
     
    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    Not Applicable
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    Not Applicable
    Item 8.Identification and Classification of Members of the Group.
     
    If a group has filed this schedule pursuant to §240.13d-1(b)(1)(ii)(K), so indicate under Item 3(k) and attach an exhibit stating the identity and Item 3 classification of each member of the group. If a group has filed this schedule pursuant to §240.13d-1(c) or §240.13d-1(d), attach an exhibit stating the identity of each member of the group.


    YA II PN, Ltd. ("YA II") entered into a Standby Equity Purchase Agreement ("SEPA") with Indaptus Therapeutics, Inc. (the "Issuer"), on February 12, 2025. Under the SEPA, the Issuer has the option to sell up to $20 million of its Common Stock to YA II, and YA II is obligated to purchase such shares, at a price and on the terms and subject to the conditions set forth in the SEPA. Under the SEPA, the Issuer is prohibited from issuing and selling shares to YA II to the extent that it would cause the aggregate number of shares of Common Stock then beneficially owned by YA II and its affiliates to exceed 9.99% of the then outstanding shares of Common Stock of the Issuer. YA II is beneficially owned by YA Global Investments II (U.S.), LP (the "YA Feeder"). Yorkville Advisors Global, LP (the "YA Advisor") is the investment manager to YA II. Yorkville Advisors Global II, LLC (the "YA Advisor GP") is the general partner to the YA Advisor. YAII GP, LP (the "YA GP") is the general partner to the YA Feeder. YAII GP II, LLC (the "Yorkville GP") is the general partner to the YA GP. Mark Angelo makes the investment decisions on behalf of YA II. Accordingly, each of YA II, YA Feeder, the YA Advisor, the YA Advisor GP, the YA GP, the Yorkville GP and Mark Angelo may be deemed affiliates and therefore may be deemed to beneficially own the same number of Class A Shares. YAII GP, LP is the general partner of SC-Sigma Global Partners, LP ("SC-Sigma"), which is an investor in YA II. YAII GP II, LLC is the general partner of YAII GP, LP. The YA Advisor is the investment manager to SC-Sigma. Accordingly, SC-Sigma, the YA GP, the Yorkville GP, the YA Advisor, and Mark Angelo may be deemed affiliates and therefore may be deemed to beneficially own the same number of shares of Class A Shares. For purposes of this filing, each of the reporting persons is deemed an affiliate of each other reporting person.
    Item 9.Notice of Dissolution of Group.
     
    Not Applicable

    Item 10.Certifications:
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    YA II PN, Ltd.
     
    Signature:/s/ David Gonzalez
    Name/Title:David Gonzalez, General Counsel
    Date:02/18/2025
     
    YA Global Investments II (U.S.), LP
     
    Signature:/s/ David Gonzalez
    Name/Title:David Gonzalez, General Counsel
    Date:02/18/2025
     
    Yorkville Advisors Global, LP
     
    Signature:/s/ David Gonzalez
    Name/Title:David Gonzalez, General Counsel
    Date:02/18/2025
     
    Yorkville Advisors Global II, LLC
     
    Signature:/s/ David Gonzalez
    Name/Title:David Gonzalez, General Counsel
    Date:02/18/2025
     
    YAII GP, LP
     
    Signature:/s/ David Gonzalez
    Name/Title:David Gonzalez, General Counsel
    Date:02/18/2025
     
    YAII GP II, LLC
     
    Signature:/s/ David Gonzalez
    Name/Title:David Gonzalez, General Counsel
    Date:02/18/2025
     
    Mark Angelo
     
    Signature:/s/ Mark Angelo
    Name/Title:Mark Angelo
    Date:02/18/2025
     
    SC-Sigma Global Partners, LP
     
    Signature:/s/ David Gonzalez
    Name/Title:David Gonzalez, General Counsel
    Date:02/18/2025
    Get the next $INDP alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $INDP

    DatePrice TargetRatingAnalyst
    1/31/2022$15.00Buy
    HC Wainwright & Co.
    10/19/2021$16.00Hold → Buy
    Maxim Group
    More analyst ratings

    $INDP
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • HC Wainwright & Co. resumed coverage on Indaptus Therapeutics with a new price target

      HC Wainwright & Co. resumed coverage of Indaptus Therapeutics with a rating of Buy and set a new price target of $15.00

      1/31/22 7:21:10 AM ET
      $INDP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Indaptus Therapeutics upgraded by Maxim Group with a new price target

      Maxim Group upgraded Indaptus Therapeutics from Hold to Buy and set a new price target of $16.00

      10/19/21 8:57:59 AM ET
      $INDP
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $INDP
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13D/A filed by Indaptus Therapeutics Inc.

      SC 13D/A - Indaptus Therapeutics, Inc. (0001857044) (Subject)

      11/26/24 4:11:08 PM ET
      $INDP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D filed by Indaptus Therapeutics Inc.

      SC 13D - Indaptus Therapeutics, Inc. (0001857044) (Subject)

      10/10/24 4:10:11 PM ET
      $INDP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Indaptus Therapeutics Inc. (Amendment)

      SC 13G/A - Indaptus Therapeutics, Inc. (0001857044) (Subject)

      7/7/22 7:40:12 PM ET
      $INDP
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $INDP
    Leadership Updates

    Live Leadership Updates

    See more
    • Indaptus Therapeutics Expands Digital Presence with Launch of Social Media Channels

      NEW YORK, Feb. 08, 2024 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (NASDAQ:INDP), a clinical stage biotechnology company dedicated to pioneering innovative cancer and viral infection treatments, is pleased to announce the launch of a new social media initiative to provide education and updates about the company. Recognizing the importance of engaging with all stakeholders, Indaptus will generate content on a variety of digital platforms, including X (formerly known as Twitter) and LinkedIn. Indaptus Therapeutics emerges from over a century of groundbreaking advancements in immunotherapy and has built an approach that is designed to stimulate a broad acting effect on the immune sy

      2/8/24 8:00:00 AM ET
      $INDP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Indaptus Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update

      NEW YORK, Nov. 06, 2023 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (NASDAQ:INDP) ("Indaptus" or the "Company") today announced financial results for the third quarter ended September 30, 2023 and provided a corporate update. "We continue to be encouraged by early results from our first cohort of patients in the INDP-D101 trial evaluating Decoy20 for the treatment of solid tumors.  As we recently reported and presented at the Society for Immunology in Cancer (SITC) conference, all four first cohort patients have maintained stable disease since receiving their single dose and presented evidence of immune activation, along with short-lived adverse events consistent with Decoy20's mech

      11/6/23 4:01:00 PM ET
      $INDP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Indaptus Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Update

      NEW YORK, Aug. 14, 2023 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (NASDAQ:INDP) ("Indaptus" or the "Company") today announced financial results for the second quarter ended June 30, 2023 and provided a corporate update. "We have recently announced the completion of the first cohort of patients in our INDP-D101 trial evaluating Decoy20 for the treatment of solid tumors and receipt of authorization from the Safety Review Committee to advance into the second cohort. As previously announced, we are pleased to observe evidence of immune activation, along with short-lived adverse events consistent with Decoy20's mechanism of action," said Jeffrey Meckler, Chief Executive Officer of Indapt

      8/14/23 8:00:00 AM ET
      $INDP
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $INDP
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • CEO and Director Meckler Jeffrey A was granted 42,553 shares, increasing direct ownership by 27% to 202,859 units (SEC Form 4)

      4 - Indaptus Therapeutics, Inc. (0001857044) (Issuer)

      11/26/24 4:12:39 PM ET
      $INDP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by CEO and Director Meckler Jeffrey A

      4 - Indaptus Therapeutics, Inc. (0001857044) (Issuer)

      10/10/24 4:05:09 PM ET
      $INDP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Chief Operating Officer Linscott Walt Addison

      4 - Indaptus Therapeutics, Inc. (0001857044) (Issuer)

      10/10/24 4:05:10 PM ET
      $INDP
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $INDP
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Indaptus Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update

      NEW YORK, May 14, 2025 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (NASDAQ:INDP) ("Indaptus" or the "Company"), a clinical stage biotechnology company dedicated to pioneering innovative cancer and viral infection treatments, today announced financial results for the first quarter ended March 31, 2025, and provided a corporate update. Jeffrey Meckler, Indaptus Therapeutics' Chief Executive Officer, commented, "We made meaningful progress in the first quarter across multiple fronts of our clinical and research programs. In March, we announced the initiation of the expansion arm of our Phase 1b/2 clinical trial of Decoy20. This arm will evaluate Decoy20 in combination with BeOn

      5/14/25 8:00:00 AM ET
      $INDP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Indaptus Therapeutics Founder and Chief Scientific Officer Dr. Michael Newman Named Chair and Expert Speaker at 6th Annual Cytokine-Based Drug Development Summit

      NEW YORK, May 08, 2025 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (NASDAQ:INDP), a clinical-stage biotechnology company dedicated to developing novel treatments for cancer and viral infections, announces that its Founder and Chief Scientific Officer, Michael Newman, Ph.D., will serve as an Expert Speaker and Chair of Day 2 at the 6th Annual Cytokine-Based Drug Development Summit taking place May 15-16, 2025 in Boston. Dr. Newman will deliver a presentation titled "Pulsed Cytokine Delivery for Anti-Tumor Immunotherapy & its Impact on Toxicity & Efficacy" on Thursday, May 15 at 12:15PM ET. He will also lead a panel discussion on pre-clinical models for cytokine drug development and del

      5/8/25 8:00:00 AM ET
      $INDP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Indaptus Therapeutics Chief Medical Officer Roger Waltzman, M.D., M.B.A. to Moderate Panel at CMO360 Summit

      NEW YORK, March 25, 2025 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (NASDAQ:INDP), a clinical-stage biotechnology company pioneering innovative therapies for cancer and viral infections, announces that its chief medical officer, Roger Waltzman, M.D., M.B.A. will be moderating a panel at the annual CMO360 Summit, being held April 7-8 in Boston. Dr. Waltzman's panel, titled "Ensuring Effective and Efficient Trials Through Clinical Operations" will be Monday, April 7th from 4:05PM – 4:35PM ET. Jeffrey Meckler, Indaptus CEO, commented, "These opportunities serve as continued validation for our approach to clinical trial management, reinforcing its potential to enhance effici

      3/25/25 8:00:00 AM ET
      $INDP
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $INDP
    SEC Filings

    See more
    • SEC Form 10-Q filed by Indaptus Therapeutics Inc.

      10-Q - Indaptus Therapeutics, Inc. (0001857044) (Filer)

      5/14/25 8:01:37 AM ET
      $INDP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 8-K filed by Indaptus Therapeutics Inc.

      8-K - Indaptus Therapeutics, Inc. (0001857044) (Filer)

      5/14/25 8:00:24 AM ET
      $INDP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form DEFA14A filed by Indaptus Therapeutics Inc.

      DEFA14A - Indaptus Therapeutics, Inc. (0001857044) (Filer)

      4/28/25 4:20:10 PM ET
      $INDP
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $INDP
    Financials

    Live finance-specific insights

    See more
    • Indaptus Therapeutics Reports Fourth Quarter and Year-End 2024 Financial Results and Provides Corporate Update

      Company Achieves Key Clinical Milestone with more than 20 Patients Enrolled in Weekly Dosing Cohort of Phase 1 Trial of Decoy20Pharmacodynamic immune activation biomarker and pharmacokinetics profiles in initial data sets appear to meet or exceed initial expectationsEarly signs of potential benefit emerge with some patients demonstrating Stable Disease NEW YORK, March 13, 2025 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (NASDAQ:INDP) ("Indaptus" or the "Company") today announces financial results for the fourth quarter and fiscal year ended December 31, 2024 and provides a corporate update. Jeffrey Meckler, Chief Executive Officer of Indaptus, commented, "We continue

      3/13/25 7:30:00 AM ET
      $INDP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Indaptus Therapeutics Announces Clinical Supply Agreement with BeiGene to Evaluate Novel Cancer Treatment Combinations

      Planned industry first clinical trial combining BeiGene's checkpoint inhibitor tislelizumab with Indaptus' broadly targeted, short duration systemic immune stimulator Decoy20 expected to start in 2025 Indaptus Therapeutics Management will hold a conference call on October 22, 2024 at 4:30PM ET to discuss the agreement and future plans NEW YORK, Oct. 22, 2024 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (NASDAQ:INDP), a clinical-stage biotechnology company pioneering innovative cancer and viral infection treatments, today announced a clinical supply agreement with BeiGene. Building on Indaptus' preclinical observation that Decoy20, when combined with a PD-1 inhibitor, induced complete

      10/22/24 8:00:00 AM ET
      $INDP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Indaptus Therapeutics Reports Third Quarter 2022 Financial Results and Provides Corporate Update

      Company Remains On Track to Initiate Phase 1 Clinical Trial of Decoy20 for Treatment of Solid Tumors in Q4 2022 NEW YORK, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (NASDAQ:INDP) ("Indaptus" or the "Company"), today announces financial results for the third quarter ended September 30, 2022 and provides a corporate update. "We continue to diligently prepare for the launch of our Phase 1 trial of Decoy20 for the treatment of solid tumors, while carefully managing our expenses," said Jeffrey Meckler, chief executive officer of Indaptus. "Once we have finalized the initiation process with our trial sites we will be prepared to speak more openly about progress, including tr

      11/10/22 4:05:00 PM ET
      $INDP
      Biotechnology: Pharmaceutical Preparations
      Health Care